CN Bio Will Host Organ-on-a-Chip Symposium in December
The virtual event will address regulatory shifts and R&D adoption strategies for human-relevant technologies.
Updated on Oct. 5, 2026 in Biotech
CN Bio has announced a virtual e-Symposium scheduled for December 2 and December 8, 2026. The free event aims to guide researchers on the adoption of organ-on-a-chip technologies.
Why it matters
The symposium responds to global legislative and regulatory changes that are accelerating the industry shift toward human-relevant testing models. It provides a platform to address technical questions regarding the integration of these tools into standard research workflows.
The program consists of four distinct sessions covering masterclass fundamentals, model development, ADME/DMPK, and toxicology. This structure benchmarks the current maturity of these platforms against traditional preclinical trial workflows.
The players
CN Bio
A developer of organ-on-a-chip microphysiological systems focused on accelerating drug discovery and preclinical development.
Novo Nordisk
A global pharmaceutical company specializing in diabetes and obesity treatments with an extensive internal drug discovery pipeline.
Bristol Myers Squibb
A global biopharmaceutical company that develops and markets medicines for oncology, hematology, and immunology.
The details
Organ-on-a-chip technologies are microfluidic devices that mimic the physiological functions of human organs by culturing cells in a controlled environment. The symposium will utilize expert-led presentations and peer case studies to demonstrate how these systems integrate into broader R&D strategies. The event covers ADME—the absorption, distribution, metabolism, and excretion of drugs—and DMPK, the study of how drug concentrations change in the body over time, to show how these chips improve toxicological data.
Timeline
December 2, 2026
December 8, 2026
The Tech Race
The symposium aligns with the broader industry transition following the FDA Modernization Act 2.0, which opened pathways for non-animal test methods. It serves as a benchmark for how specialized biotech firms are standardizing these models to meet emerging regulatory compliance requirements.
Researchers and industry professionals can attend the virtual sessions for free to gain insight into implementing these technologies in their own R&D pipelines. The on-demand availability allows for flexible integration into existing laboratory and project schedules.
The takeaway
This event signals the increasing formalization of organ-on-a-chip protocols as companies prepare for new regulatory standards. Watch for the released session content in December to see how specific metrics like ADME/DMPK performance are being benchmarked against legacy testing methods.
What happens next
The symposium sessions are scheduled for December 2 and December 8, 2026, and will be available for viewing live or on-demand.
Further reading
Explore more on the current industry trajectory in our Biotech section.
Source note: This article includes information reported by News-Medical.
